Prevalence of Neutralizing Antibodies to AAV2 and AAV9 in Individuals with Niemann-Pick Disease, Type C1
Human Gene Therapy · 2025
DOI: 10.1089/hum.2024.233 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Gene Therapy, 2025. Verfasst von Avani V Mylvara und 4 weiteren Autor:innen. Beteiligte Einrichtung: Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Department of Human Health and Servic…. Hauptthemen laut MEDLINE: Dependovirus, Antibodies, Neutralizing, Niemann-Pick Disease, Type C, Antibodies, Viral. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Intramural NIH HHS.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Department of Human Health and Services, Bethesda, Maryland, USA.
- National Human Genome Research Institute, National Institutes of Health, Department of Human Health and Services, Bethesda, Maryland, USA.
ORCID-Profile: Avani V Mylvara, Cristin D Davidson, Derek Alexander, Charles P Venditti, Forbes D Porter
Förderung
- Intramural NIH HHS
Zitieren
APA
Mylvara, A. V., Davidson, C. D., Alexander, D., Venditti, C. P., & Porter, F. D. (2025). Prevalence of Neutralizing Antibodies to AAV2 and AAV9 in Individuals with Niemann-Pick Disease, Type C1. Human Gene Therapy. https://doi.org/10.1089/hum.2024.233
Vancouver
Mylvara AV, Davidson CD, Alexander D, Venditti CP, Porter FD. Prevalence of Neutralizing Antibodies to AAV2 and AAV9 in Individuals with Niemann-Pick Disease, Type C1. Human Gene Therapy. 2025. doi:10.1089/hum.2024.233
BibTeX
@article{Mylvara2025,
author = {Mylvara, Avani V and Davidson, Cristin D and Alexander, Derek and Venditti, Charles P and Porter, Forbes D},
title = {Prevalence of Neutralizing Antibodies to AAV2 and AAV9 in Individuals with Niemann-Pick Disease, Type C1},
journal = {Human Gene Therapy},
year = {2025},
doi = {10.1089/hum.2024.233}
}
EUVIMED